ASP 7035

Drug Profile

ASP 7035

Alternative Names: ASP-7035

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Tacurion Pharma
  • Class Acetamides; Small molecules; Urologics
  • Mechanism of Action Vasopressin V2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nocturia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Nocturia in Japan (PO, Tablet)
  • 09 Dec 2013 Phase-II clinical trials in Nocturia in Belgium, Poland and Romania (PO) (EudraCT2013-003701-25)
  • 07 May 2013 ASP 7035 licensed to Tacurion Pharma worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top